Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable pharmaceutical manufacturing, on Monday provided an overview of its 2025 corporate developments and outlined strategic priorities for 2026. The company also confirmed plans for a pending corporate name change to Quantum Genesis AI Corp. and a corresponding trading symbol change, subject to FINRA and regulatory approvals.
During 2025, Quantumzyme advanced its operations as an early-stage biotechnology company concentrating on enzyme research and development for sustainable chemistry applications. Key activities included improving regulatory reporting and disclosure practices, progressing internal research in enzyme engineering and biocatalytic process development for pharmaceutical and specialty chemical uses, and publishing U.S. and international patent applications related to enzymatic processes. The company cautioned that patent applications remain pending with no assurance of grant or commercial protection.
Quantumzyme also updated its corporate website and communications to better articulate its business focus and long-term objectives. Throughout the year, the company maintained a focus on foundational research, capital discipline, and regulatory compliance while navigating typical early-stage biotech challenges.
A significant shift in 2025 was the expansion of artificial intelligence and computational research. Quantumzyme began evaluating machine learning techniques and computational modeling to support enzyme discovery, structure-function analysis, and research prioritization. These AI initiatives are intended to complement laboratory research by improving experimental design and data analysis efficiency. The company emphasized that the use of AI tools remains exploratory and focused on internal decision support, subject to technical, financial, and operational limitations.
In late 2025, the Board of Directors approved a proposal to change the legal name to Quantum Genesis AI Corp., reflecting a greater emphasis on computational and data-driven approaches within enzyme research. The company has submitted required documentation, and the name and symbol change are expected to be completed during the first quarter of 2026, pending FINRA approval.
For 2026, Quantumzyme outlined several strategic priorities: advancing enzyme candidates and biocatalytic pathways through internal testing and optimization; continuing to refine computational modeling and AI-driven research tools; exploring potential collaborations, licensing, or development opportunities with pharmaceutical and chemical industry participants; increasing visibility through scientific forums and investor communications; and assessing long-term corporate objectives including reporting status and capital planning. The company cautioned that these objectives are subject to risks including technical challenges, capital availability, regulatory considerations, and market conditions.
More information is available at www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
